Regulations

DermaRite Industries, LLC Receives Warning Letter from FDA

The Center for Drug Evaluation and Research (CDER) cited nonprescription/OTC issues.

The United States Food and Drug Administration (FDA) inspected DermaRite Industries, LLC’s manufacturing facility in North Bergen, NJ and issued a violation as seen from March 26 to April 8, 2025. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, according to the letter. The Center for Drug Evaluation and Research (CDER) cited nonprescription/OTC issues. The FDA noted: “Because your methods, faci...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters